Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-015758
Filing Date
2025-06-20
Accepted
2025-06-20 09:46:33
Documents
73
Period of Report
2025-04-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1394882
2 EX-10.6 ex10-6.htm EX-10.6 201227
3 EX-31.1 ex31-1.htm EX-31.1 12495
4 EX-31.2 ex31-2.htm EX-31.2 12851
5 EX-32.1 ex32-1.htm EX-32.1 6415
6 EX-32.2 ex32-2.htm EX-32.2 6944
  Complete submission text file 0001641172-25-015758.txt   8029059

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE vtro-20250430.xsd EX-101.SCH 67980
8 XBRL CALCULATION FILE vtro-20250430_cal.xml EX-101.CAL 79109
9 XBRL DEFINITION FILE vtro-20250430_def.xml EX-101.DEF 253552
10 XBRL LABEL FILE vtro-20250430_lab.xml EX-101.LAB 519806
11 XBRL PRESENTATION FILE vtro-20250430_pre.xml EX-101.PRE 369831
75 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1354384
Mailing Address 3200 CHERRY CREEK DRIVE SOUTH SUITE 410 DENVER CO 80209
Business Address 3200 CHERRY CREEK DRIVE SOUTH SUITE 410 DENVER CO 80209 8558487627
Vitro Biopharma, Inc. (Filer) CIK: 0000793171 (see all company filings)

EIN.: 841012042 | State of Incorp.: NV | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-41766 | Film No.: 251059384
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)